Nuevecor lands $24m Series A

Nuevocor, a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, has secured $24 million in Series A financing.

Nuevocor, a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, has secured $24 million in Series A financing. EVX Ventures and Boehringer Ingelheim Venture Fund led the round.

Source: Press Release